RU2009146008A - SYNERGICAL PHARMACEUTICAL COMBINATION FOR TREATMENT OF CANCER - Google Patents
SYNERGICAL PHARMACEUTICAL COMBINATION FOR TREATMENT OF CANCER Download PDFInfo
- Publication number
- RU2009146008A RU2009146008A RU2009146008/15A RU2009146008A RU2009146008A RU 2009146008 A RU2009146008 A RU 2009146008A RU 2009146008/15 A RU2009146008/15 A RU 2009146008/15A RU 2009146008 A RU2009146008 A RU 2009146008A RU 2009146008 A RU2009146008 A RU 2009146008A
- Authority
- RU
- Russia
- Prior art keywords
- cancer
- cdk inhibitor
- pharmaceutically acceptable
- acceptable salt
- pharmaceutical combination
- Prior art date
Links
- YILZFXDHRZARQB-UHFFFAOYSA-N CN(CC1)C(CO)C1c(c(OC([AlH2])=C1)c(c(O)c2)C1=O)c2O Chemical compound CN(CC1)C(CO)C1c(c(OC([AlH2])=C1)c(c(O)c2)C1=O)c2O YILZFXDHRZARQB-UHFFFAOYSA-N 0.000 description 1
Abstract
1. Фармацевтическая комбинация, включающая цитотоксическое противоопухолевое средство, выбранное из группы, включающей паклитаксел, доцетаксел, доксорубицин и гемцитабин или их фармацевтически приемлемую соль; и ингибитор CDK или энантиомер, или фармацевтически приемлемую соль, или сольват его, где указанный ингибитор CDK представлен следующей формулой I: ! , ! где Ar представляет собой фенил, который замещенный или незамещенный 1, 2 или 3 идентичными или различными заместителями, выбранными из: галогена, выбранного из хлора, брома, фтора или йода, нитро, циано, С1-С4-алкила, трифторметила, гидроксила, С1-С4-алкокси, карбокси, С1-С4-алкоксикарбонила, CONH2 и NR1R2; где R1 и R2 каждый независимо выбран из водорода или C1-C4-алкила. ! 2. Фармацевтическая комбинация по п.1, где ингибитор CDK является соединением формулы I, где фенильная группа замещена 1, 2 или 3 идентичными или разными заместителями, выбранными из: галогена, выбранного из хлора, брома, фтора или йода, С1-С4-алкила или трифторметила. !3. Фармацевтическая комбинация по п.2, где ингибитор CDK является соединением формулы I, где фенильная группа замещена 1, 2 или 3 галогенами, выбранными из хлора, брома, фтора или йода. ! 4. Фармацевтическая комбинация по п.3, где ингибитор CDK является соединением формулы I, где фенильная группа замещена хлором. ! 5. Фармацевтическая комбинация по п.2, где ингибитор CDK является соединением формулы I, где фенильная группа замещена 1, 2 или 3 трифторметильными группами. ! 6. Фармацевтическая комбинация по п.1, где ингибитор CDK представлен соединением формулы I, которое представляет собой (+)-trans-2-(2-хлор-фенил)-5,7-дигидрокси-8-(2-гидроксиметил-1-метил-пирролидин-3-ил)-хромен-4 1. A pharmaceutical combination comprising a cytotoxic antitumor agent selected from the group consisting of paclitaxel, docetaxel, doxorubicin and gemcitabine or a pharmaceutically acceptable salt thereof; and a CDK inhibitor or enantiomer, or a pharmaceutically acceptable salt, or a solvate thereof, wherein said CDK inhibitor is represented by the following formula I:! ! where Ar represents phenyl, which is substituted or unsubstituted with 1, 2 or 3 identical or different substituents selected from: halogen selected from chlorine, bromine, fluorine or iodine, nitro, cyano, C1-C4 alkyl, trifluoromethyl, hydroxyl, C1 -C4 alkoxy, carboxy, C1-C4 alkoxycarbonyl, CONH2 and NR1R2; where R1 and R2 are each independently selected from hydrogen or C1-C4 alkyl. ! 2. The pharmaceutical combination according to claim 1, where the CDK inhibitor is a compound of formula I, where the phenyl group is substituted by 1, 2 or 3 identical or different substituents selected from: halogen selected from chlorine, bromine, fluorine or iodine, C1-C4- alkyl or trifluoromethyl. ! 3. The pharmaceutical combination of claim 2, wherein the CDK inhibitor is a compound of formula I, wherein the phenyl group is substituted with 1, 2, or 3 halogens selected from chlorine, bromine, fluorine, or iodine. ! 4. The pharmaceutical combination according to claim 3, where the CDK inhibitor is a compound of formula I, where the phenyl group is substituted with chlorine. ! 5. The pharmaceutical combination according to claim 2, where the CDK inhibitor is a compound of formula I, where the phenyl group is substituted by 1, 2 or 3 trifluoromethyl groups. ! 6. The pharmaceutical combination according to claim 1, where the CDK inhibitor is represented by a compound of formula I, which is (+) - trans-2- (2-chloro-phenyl) -5,7-dihydroxy-8- (2-hydroxymethyl-1 -methyl-pyrrolidin-3-yl) -chromen-4
Claims (28)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2009146008/15A RU2438664C2 (en) | 2007-05-15 | 2007-05-15 | Synergetic pharmaceutical combination for cancer treatment |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2009146008/15A RU2438664C2 (en) | 2007-05-15 | 2007-05-15 | Synergetic pharmaceutical combination for cancer treatment |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2009146008A true RU2009146008A (en) | 2011-06-20 |
RU2438664C2 RU2438664C2 (en) | 2012-01-10 |
Family
ID=44737531
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2009146008/15A RU2438664C2 (en) | 2007-05-15 | 2007-05-15 | Synergetic pharmaceutical combination for cancer treatment |
Country Status (1)
Country | Link |
---|---|
RU (1) | RU2438664C2 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10568887B2 (en) | 2015-08-03 | 2020-02-25 | Tolero Pharmaceuticals, Inc. | Combination therapies for treatment of cancer |
US10624880B2 (en) | 2015-04-20 | 2020-04-21 | Tolero Pharmaceuticals, Inc. | Predicting response to alvocidib by mitochondrial profiling |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX362905B (en) * | 2013-03-04 | 2019-02-25 | Astrazeneca Ab | Combination treatment. |
CA2937655C (en) | 2014-01-24 | 2022-06-28 | Lam Therapeutics, Inc. | Apilimod compositions for cancer treatment |
RU2671857C1 (en) * | 2014-10-30 | 2018-11-07 | Дельта-Флай Фарма, Инк. | New method for production of lipoplex for local introduction and anti-tumor medication that uses such lipoplex |
US20190209576A1 (en) * | 2014-11-07 | 2019-07-11 | AI Therapeutics, Inc. | Apilimod for use in the treatment of colorectal cancer |
EP3215158B1 (en) | 2014-11-07 | 2019-05-08 | AI Therapeutics, Inc. | Apilimod for use in the treatment of renal cancer |
US20180280407A1 (en) * | 2014-11-07 | 2018-10-04 | Tolero Pharmaceuticals, Inc. | Methods to target transcriptional control at super-enhancer regions |
PT3298021T (en) | 2015-05-18 | 2019-08-05 | Tolero Pharmaceuticals Inc | Alvocidib prodrugs having increased bioavailability |
WO2018094275A1 (en) | 2016-11-18 | 2018-05-24 | Tolero Pharmaceuticals, Inc. | Alvocidib prodrugs and their use as protein kinase inhibitors |
US11497756B2 (en) | 2017-09-12 | 2022-11-15 | Sumitomo Pharma Oncology, Inc. | Treatment regimen for cancers that are insensitive to BCL-2 inhibitors using the MCL-1 inhibitor alvocidib |
KR20210099066A (en) | 2018-12-04 | 2021-08-11 | 스미토모 다이니폰 파마 온콜로지, 인크. | CDK9 inhibitors and polymorphs thereof for use as agents for the treatment of cancer |
JP2022525149A (en) | 2019-03-20 | 2022-05-11 | スミトモ ダイニッポン ファーマ オンコロジー, インコーポレイテッド | Treatment of Acute Myeloid Leukemia (AML) with Venetoclax Failure |
-
2007
- 2007-05-15 RU RU2009146008/15A patent/RU2438664C2/en not_active IP Right Cessation
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10624880B2 (en) | 2015-04-20 | 2020-04-21 | Tolero Pharmaceuticals, Inc. | Predicting response to alvocidib by mitochondrial profiling |
US10568887B2 (en) | 2015-08-03 | 2020-02-25 | Tolero Pharmaceuticals, Inc. | Combination therapies for treatment of cancer |
US10682356B2 (en) | 2015-08-03 | 2020-06-16 | Tolero Pharmaceuticals, Inc. | Combination therapies for treatment of cancer |
US10835537B2 (en) | 2015-08-03 | 2020-11-17 | Sumitomo Dainippon Pharma Oncology, Inc. | Combination therapies for treatment of cancer |
Also Published As
Publication number | Publication date |
---|---|
RU2438664C2 (en) | 2012-01-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2009146008A (en) | SYNERGICAL PHARMACEUTICAL COMBINATION FOR TREATMENT OF CANCER | |
ES2622559T3 (en) | Therapeutic combination comprising a cdk inhibitor and an antineoplastic agent | |
RU2005140570A (en) | PHARMACEUTICAL COMPOSITION CONTAINING A HISTONDEACETYLASE INHIBITOR | |
RU2013127655A (en) | PHARMACEUTICAL COMBINATION OF PAKLITAXEL AND CDK INHIBITOR | |
EA200970932A1 (en) | METHODS OF TREATMENT WITH THE APPLICATION OF PYRIDOPYRIMIDINONOVES INHIBITORS PI3K ALPHA | |
EA201490489A1 (en) | PURINUM DERIVATIVES AND THEIR APPLICATION AS A TALL-SIMILAR RECEPTOR MODULATORS 7 | |
MX2016006919A (en) | Nucleotides for the treatment of liver cancer. | |
EA200970935A1 (en) | TREATMENT METHODS WITH THE APPLICATION OF PI3K-ALPHA HYNAXOLINE INHIBITORS | |
CY1116688T1 (en) | MODIFICATIONS OF PHARMACEUTICAL PROPERTIES OF THERAPEUTIC PRODUCTS | |
EA201001412A1 (en) | PIM KINASE INHIBITORS AND METHODS OF THEIR APPLICATION | |
EA200901155A1 (en) | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTIC PREPARATIONS (OPTIONS) AND THEIR USE IN THERAPY | |
EA201001455A1 (en) | Pyridine and pyrazine as PI3K inhibitors (phosphatidylinositin kinase-3) | |
ECSP088747A (en) | PIRAZOLES AS INHIBITORS OF THE 11-BETA-HSD1 | |
RU2011148954A (en) | PYROLIDINE-SUBSTITUTED FLAVONS AS RADIOSENSIBILIZERS FOR USE IN TREATMENT OF CANCER | |
NO20090835L (en) | New HIV reverse transcriptase inhibitors | |
DK2298768T3 (en) | 5-Amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2H-pyrido [2,3-d] pyrimidine derivatives and related compounds for the treatment of cancer | |
GEP20135925B (en) | Inhibitors of hedgehog pathway | |
EA201100971A1 (en) | DERIVATIVES OF PYRIMIDININDOL FOR THE TREATMENT OF MALIGNANT NORMALIZATION | |
SG194048A1 (en) | Combinations of akt inhibitor compounds and chemotherapeutic agents, and methods of use | |
EA200971115A1 (en) | NEW HIV REVERSE TRANSCRIPTASE INHIBITORS | |
EA201490472A1 (en) | COMBINED CANCER THERAPY FOR HSP90 INHIBITOR AND ANTIMETABOLITIS | |
EA201300420A1 (en) | COMBINATIONS WHICH CONTAIN N SUBSTITUTED N- (2-ARYLAMINO) ARYLSULPHONAMIDE | |
RU2013141559A (en) | METHOD FOR INHIBITING HAMARTOMA TUMOR CELL CELLS | |
CO2023007504A2 (en) | Tricyclic carboxamide derivatives as prmt5 inhibitors | |
RU2010140890A (en) | IMPROVED METHODS OF ANTITUMOR TREATMENT |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC43 | Official registration of the transfer of the exclusive right without contract for inventions |
Effective date: 20130821 |
|
PD4A | Correction of name of patent owner | ||
MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20160516 |